



2418

IN THE UNITED STATE PATENT AND TRADEMARK OFFICE

In re the Application of: **Garvey et al**

Application No: **10/694,183**

Group Art Unit: **1616**

Filed: **October 28, 2003**

Examiner: **A. N. Pryor**

For: **Phosphodiesterase Inhibitors and Nitric Oxide Donors, Compositions and Methods of Use**

Attorney Docket No: **102258.287 US4**

Commissioner of Patents
PO Box 1450
Alexandria, VA 22313-1450

Response to Supplemental Restriction Requirement

This response is submitted in reply to the Supplemental Election/Restriction Requirement dated November 3, 2006, for which a response is due on or before December 3, 2006.

No fee is believed to be due; however, the Commissioner is authorized to charge any necessary fees or credit any overpayments to Deposit Account No. 08-0219 to maintain the pendency of the present application.

Remarks

In response to the election of species requirement for a specific arginine compound, Applicants elect L-arginine, with traverse.

An early and favorable consideration and allowance of the pending claims is respectfully requested.

Respectfully submitted,

Belinda M. Lew, Ph.D.
Registration No. 53,212

Dated: November 28, 2006
Wilmer Cutler Pickering Hale and Dorr LLP
1875 Pennsylvania Avenue, NW
Washington, DC 20006
Phone: (202) 663-6029